Madrigal Pharmaceuticals
A clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), a liver disease with high unmet medical need.
The company has advanced its lead candidate, resmetirom, a once daily, oral, thyroid hormone receptor (THR) β-selective agonist, into four Phase III clinical trials in NASH. Based on positive results reported to date, Madrigal believes resmetirom has the potential to become the first medication approved for the treatment of patients with NASH.
Latest Madrigal Pharmaceuticals News & Features
9 April 2024
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze